Recent Advances in Anti-Angiogenic Therapy of Cancer

Rajeev S. Samant; Lalita A. Shevde

doi:10.18632/oncotarget.234

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Recent Advances in Anti-Angiogenic Therapy of Cancer

Rajeev S. Samant and Lalita A. Shevde _

PDF | HTML | How to cite

Oncotarget. 2011; 2:122-134. https://doi.org/10.18632/oncotarget.234

Metrics: PDF 3816 views | HTML 6684 views | ?

Abstract

Rajeev S. Samant and Lalita A. Shevde

^*Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Keywords: angiogenesis, tumor progression, metastasis, VEGF, angiogenesis inhibitors

Received: February 28, 2011; Accepted: March 7, 2011; Published: March 7, 2011;

Correspondence:

Rajeev S. Samant, e-mail:

Lalita A. Shevde, e-mail:

Abstract

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 234

Publication Alerts

Reviews:

Recent Advances in Anti-Angiogenic Therapy of Cancer

Abstract